Role of Neoadjuvant Chemotherapy in the Management of Stage IIIC–IV Ovarian Cancer: Survey Results from the Members of the European Society of Gynecological Oncology

Objective The aim of this study is to evaluate the current opinion of the members of the European Society of Gynecological Oncology (ESGO) on the use of neoadjuvant chemotherapy (NACT) in stage IIIC and IV ovarian cancer. Methods A link to a 21-item questionnaire, with questions about the management of patients with stage IIIC and IV ovarian cancer, was sent 3 times to the ESGO members (N = 1177). Results Of the 469 (40%) responding members, 70.2% believe there is sufficient evidence to use NACT followed by interval debulking for the treatment of stage IIIC and IV ovarian cancer. On the basis of a multivariable logistic regression analysis, no relationships between the belief in evidence for NACT and practice type (P = 0.15) or level of experience (P = 0.41) were observed. Only 5.3% of respondents never use NACT, and 30% uses NACT in less than 10% of their patients. Optimal debulking, defined as “no macroscopic residual tumor,” is reported in more than 60% of the patients by 20% of the respondents at primary debulking, and by 34.6% of the respondents when interval debulking is performed. Whether a patient can be optimally primarily debulked is impossible to determine preoperatively according to 51.1% of the respondents. Computed tomographic scan (79.4%) and clinical examination (72.5%) are regarded as the most important modalities to predict operability. Diagnostic laparoscopy is used by 46.3% of the respondents. The most important reasons for choosing NACT are bulky disease in the upper abdomen (64.7%) and stage IV disease (58.7%). Conclusions Of the responding ESGO members, 70% believe there is sufficient evidence to treat patients with stage IIIC–IV ovarian cancer with NACT, and 30% uses NACT in less than 10% of their patients.

[1]  Christian Marth,et al.  2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer: Report From the Fourth Ovarian Cancer Consensus Conference , 2011, International Journal of Gynecologic Cancer.

[2]  W. Lichtenegger,et al.  Primary Versus Interval Debulking Surgery in Advanced Ovarian Cancer: Results From a Systematic Single-Center Analysis , 2010, International Journal of Gynecologic Cancer.

[3]  B. Rimel,et al.  The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists. , 2010, Gynecologic oncology.

[4]  G. Kenter,et al.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.

[5]  I. Vergote,et al.  Patterns of care in surgery for ovarian cancer in Europe. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[6]  S. Kehoe,et al.  When Should Surgical Cytoreduction in Advanced Ovarian Cancer Take Place? , 2009, Journal of oncology.

[7]  I. Vergote,et al.  Surgical program building in advanced ovarian cancer: European perspective. , 2009, Gynecologic oncology.

[8]  B. Nam,et al.  Does Neoadjuvant Chemotherapy Increase Optimal Cytoreduction Rate in Advanced Ovarian Cancer? Meta-Analysis of 21 Studies , 2009, Annals of Surgical Oncology.

[9]  A. Reuss,et al.  Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials , 2009, Cancer.

[10]  I. Vergote,et al.  EORTC-GCG process quality indicators for ovarian cancer surgery. , 2009, European journal of cancer.

[11]  P. Colombo,et al.  Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[12]  Jacobus Pfisterer,et al.  Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. , 2009, Gynecologic oncology.

[13]  I Vergote,et al.  Timing of debulking surgery in advanced ovarian cancer , 2008, International Journal of Gynecologic Cancer.

[14]  R. Ozols,et al.  Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  D. Levine,et al.  What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? , 2007, Gynecologic oncology.

[16]  D. Chi,et al.  Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. , 2006, Gynecologic oncology.

[17]  C. Tropé,et al.  Primary surgery for ovarian cancer. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[18]  J. Kurtinaitis,et al.  Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients , 2006, BMC Cancer.

[19]  D. Atallah,et al.  Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. , 2003, Journal of the American College of Surgeons.

[20]  M. Johnston,et al.  Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. , 2002, Gynecologic oncology.

[21]  E. Trimble,et al.  Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  N. Spirtos,et al.  Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival? , 2001, Gynecologic oncology.

[23]  P. Schwartz,et al.  Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. , 1999, Gynecologic oncology.

[24]  P. V. van Dam,et al.  Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. , 1998, Gynecologic oncology.

[25]  Gary G. Koch,et al.  Categorical Data Analysis Using The SAS1 System , 1995 .

[26]  S. Orsulic,et al.  Ovarian Cancer , 1993, British Journal of Cancer.

[27]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.